Posted on

Ketamine Wellness Centers (KWC) Announces Partnership With The Veterans Administration (VA) in Arizona

Ketamine Wellness Centers (KWC) Announces Partnership With The Veterans Administration (VA) in Arizona

Nation’s Largest Ketamine Therapy Provider to Cover Out-Of-Pocket Costs for Veterans Experiencing Treatment-resistant Depression, PTSD and Anxiety

GILBERT, AZ, May 12, 2022 – Ketamine Wellness Centers (KWC), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today announced a new partnership with the Veterans Administration (VA) in Arizona. Veterans suffering from treatment-resistant depression, PTSD and anxiety will have access to ketamine therapy at the KWC Arizona clinics in Phoenix, Tucson and Mesa-Gilbert at no out-of-pocket cost with prior authorization from the VA. This new VA partnership is in addition to the one established with the KWC located in Burnsville, Minnesota.

More than 20 million veterans live in the United States and the state of Arizona is home to upwards of 500,000 veterans. The Office of Disease Prevention and Health Promotion found that veterans of all ages in Arizona are three times more likely to die by suicide than non-veterans, and veterans over the age of 65 are at four times greater risk of dying by suicide than non-veterans. Unfortunately, one-third of veterans know of a fellow former service member who is not currently receiving the necessary mental health care. 

The nation’s largest ketamine therapy provider is one of the few ketamine providers in the U.S. authorized to partner with the VA and remains committed to offering exceptional, therapeutic services that meet the needs of each veteran seeking quality mental health care. In addition to the VA partnership, KWC also partnered with the Veterans Administration (VA) Community Care Network last year to offer ketamine treatments to veterans at no out-of-pocket cost at their locations in Burnsville and Naperville, Illinois. These partnerships are in addition to the Hero Discount offered at clinics nationwide to cover partial out-of-pocket expenses of the treatment for military veterans and first responders. 

“At KWC, we take great pride in supporting our veterans in Arizona and across the country. Unfortunately, veterans often face challenges securing the care they seek, such as access and affordability, and our partnership with the Veterans Administration will help to alleviate some of them,” Kevin Nicholson, CEO of KWC and COO of Delic, said. “The VA is a dedicated service organization that shares our commitment to supporting our veterans on the path to securing the mental health services they need to gain control over their lives again. We anticipate even more VA contracts as a result of the resources KWC has committed to expanding insurance coverage for our patients.” 

For more information about Ketamine Wellness Centers’ locations, services and hours of operation, please visit https://www.ketaminewellnesscenters.com/locations/.

About Ketamine Wellness Centers

Ketamine Wellness Centers (KWC) is the largest ketamine therapy provider in the United States with 13 clinic locations serving communities across nine states. Since 2011 KWC has been a trusted leader in bringing IV ketamine therapy into mainstream health care. KWC has provided over 60,000 treatments to clinically eligible patients, from young adults to seniors, in addition to developing specialized programs for veterans and first responders. The KWC team, including a core group of physicians, psychologists, clinicians, and executives, is dedicated to providing value-based, personalized, clinically controlled ketamine infusion care for people suffering from treatment-resistant depression, anxiety, PTSD, OCD and chronic pain. KWC’s scalable business and treatment model is designed for further rapid expansion along with breakthrough innovations in effective therapies and services.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

Investor Relations Contact
Rich Rodriguez 
rich@deliccorp.com

Media Contact
MATTIO Communications
Clare Redlick 
delic@mattio.com

Posted on

Wellbeing Digital Sciences Subsidiary IRP Health Approved as Part of Coveted Chronic Pain Centre of Excellence for Canadian Veterans Network

Wellbeing Digital Sciences Subsidiary IRP Health Approved as Part of Coveted Chronic Pain Centre of Excellence for Canadian Veterans Network

The Company’s Ottawa-Based IRP Health Clinic has Also Been Approved by Veterans Affairs Canada for its Reactivation Program  

Vancouver, British Columbia, April 28, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc.  (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based  mental healthcare company focused on the development and implementation of innovative clinical  solutions such as psychedelic medicine and digital therapeutics supported by clinical research, is pleased to  announce that its subsidiary, IRP Health Ltd. (“IRP Health” or the “Subsidiary”), has been approved as  part of the Chronic Pain Centre of Excellence for Canadian veterans (“CPCoE”). Additionally, IRP  Health’s clinic in Ottawa, Ontario (the “Ottawa Clinic”) has been approved by Veterans Affair Canada  (“VAC”) for its multidisciplinary Reactivation-branded therapy program (“Reactivation”).  

CPCoE  

After meeting strict criteria, IRP Health’s four Canadian locations will now be listed and recommended as  part of the national network of clinics. The clinics will contribute towards the national collection of data to  help further research and innovation with respect to the treatment of military veterans. The CPCoE provides  national leadership for research co-designed with veterans and their families and supports the  implementation of this research with a national network of clinics to help veterans and their families manage  their pain and reconnect with life.  

Thanks to CAD 20 million in funding from VAC over five years, the CPCoE strives to be a leader in  veteran-first chronic pain research and improving care.. The CPCoE is already the national leader in  researching chronic pain inveterans. Its guiding principles for research include national and international  collaborations, building upon its existing strengths in Canada, and capitalizing on the investments made by  VAC. With the goal of improving veterans’ wellbeing, the CPCoE’s research findings will be used to  promote evidence-based best practices to inform a network of pain clinics, researchers, case managers and  the public. More information can be found by visiting the following website:  https://www.veteranschronicpain.ca/  

Ottawa Clinic 

IRP Health’s Ottawa Clinic has been approved by VAC to begin offering the Reactivation therapy program  at the location. Reactivation is a 12-week, physician-supervised, interdisciplinary pain management  program that assists veterans with chronic musculoskeletal injuries and pain. It aims to help veterans return  to behaviours that are consistent with being well, rather than behaviours that are consistent with suffering.  The goals of Reactivation are to decrease distressing symptoms, increase engagement in the community  and increase the ability to complete daily tasks and also strives to reduce patient disability in both the short  and long term, while giving veterans better control and understanding of their pain and health challenges.  The therapy program combines psychiatry, psychology, occupational therapy, physiotherapy, kinesiology,  and dietetics to provide an interdisciplinary approach and a cutting-edge treatment.  

VAC is a government organization for current and former members of the Canadian Armed Forces, Royal  Canadian Mounted Police and their family members which strives to provide services and benefits intended  to improve the well-being of the veterans and their kin. The approval of the Reactivation program in the  Ottawa Clinic has the potential to make a difference in the lives of many veterans who are coping with  mental and physical illnesses. More information about VAC can be found on its website:  https://www.veterans.gc.ca/eng 

Management Commentary  

“Being recognised by Canada’s leader in chronic pain research and services for military veterans is both a  privilege and an honour. The support and guidance we have received through the CPCoE to this point has  been integral in developing our foundation for growth and we look forward to supporting them through  furthering their national data collection,” said Steven Inglefield, Chief Executive Officer of IRP Health and  Chief Operating Officer of Wellbeing.  

“We are pleased that IRP Health continues to make strides toward improving the lives of veterans and first  responders through the Reactivation program. To be recognized as being a national network of clinics that  works with Canadian veterans, IRP Health is evolving in positive ways. We are proud of the Subsidiary for  becoming part of the CPCoE and helping veterans and their families. As part of Wellbeing, IRP Health is  focused on enriching the lives of its patients and raising the bar for outstanding mental healthcare,” said  Najla Guthrie, Chief Executive Officer of Wellbeing.  

ABOUT IRP HEALTH  

Founded in 2016, IRP began as a rehabilitation and performance centre offering exercise therapy and  rehabilitation programs in Victoria, British Columbia. IRP builds safe and supportive environments while  demonstrating modern, evidence-based physical rehabilitation programs designed specifically for the needs  of veterans and first responders. Building on the success of over 15,000 treatments in the flagship Victoria  location. IRP is adding new locations and programs to improve access to much needed treatments. More  information about IRP Health can be found on its website: https://www.irphealth.ca 

ABOUT WELLBEING DIGITAL SCIENCES  

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the  development and implementation of innovative clinical solutions, including psychedelic medicine and  digital therapeutics, as supported by clinical research. Its mission is supported by a network of North  American clinics that provide forward-thinking therapies and other types of treatment to patients as well as  through a contract research organization that offers clinical trials services to clients pursuing drug  development. In essence, the Company exists to make breakthrough treatments more accessible and to offer  patients transformational experiences. 

On behalf of:  

WELLBEING DIGITAL SCIENCES INC. 

“Najla Guthrie” 

Najla Guthrie, CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  

Email: ir@wellbeingdigital.co  

Web: www.wellbeingdigital.co 

Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding  the Company’s business, assets or investments, as well other statements that are not historical facts. Readers  are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that  the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking  statements involve numerous assumptions, known and unknown risks and uncertainties, both general and  specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to  differ materially from any estimates or projections of future performance or results expressed or implied by  such forward-looking statements. These assumptions, risks and uncertainties include, among other things,  the state of the economy in general and capital markets in particular, investor interest in the business and  prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release.  Except as required by law, the Company disclaims any intention and assumes no obligation to update or  revise any forward-looking statements, whether as a result of new information, future events or otherwise,  except as required by applicable securities law. Additionally, the Company undertakes no obligation to  comment on the expectations of, or statements made, by third parties in respect of the matters discussed  above.  

Posted on

“It’s been 50 years since the war and I finally came home”

GoDaddy Billionaire Bob Parsons Believes Psychedelics Can Heal Trauma—And He’s Putting His Money (And Brain) On The Line

Bob Parsons, founder of GoDaddy, suffered from PTSD after witnessing “grisly combat” in the Vietnam War. 

It wasn’t until he went through a multiday therapy treatment with psilocybin, ayahuasca, and LSD that he began to feel like his old self again. 

“What I think psychedelics did was a reset. Now, I’m like people who haven’t been in combat to a certain degree,” he believes. 

Bob is on a mission to help other veterans battling PTSD. He donated $5M to Mount Sinai’s psychedelic research center to fund MDMA therapy training for healthcare practitioners. 

PDF of article

Posted on

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Study further supports the expansion of clinical trials of MYCO-001 for the treatment of PTSD among the Veteran population

DENVER, Jan. 24, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress (Combat Stress) and the King’s College London to utilize psilocybin as part of a psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (PTSD) in veterans. Combat Stress will be one of several sites for Mydecine’s upcoming clinical trials.

Combat Stress is the leading charity aiding veterans’ mental health in the United Kingdom, providing treatment and support to former servicemen and women for over a century. They provide a range of online, community, outpatient and residential specialist mental health services to veterans with complex mental health issues related to their military service.

Professor Dominic Murphy, Head of Research at Combat Stress and President of the UK Psychological Trauma Society, has been named a Principal Investigator for the study which will utilize Mydecine’s lead psilocybin drug candidate, MYCO-001, as an adjunct to psychotherapy to treat severe PTSD in veterans that has otherwise been resistant to traditional forms of therapy. Data collected from the study will further advance Mydecine’s drug development pipeline and their ability to bring a much needed novel treatment to market.

“I am truly excited to be leading this study at Combat Stress,” stated Professor Murphy. “We know that the gold standard treatments for PTSD, provided by Combat Stress and other organizations, work for most veterans. However, for a minority, their symptoms do not improve. This collaboration offers great potential for research focused on new, innovative therapeutics that offer significant opportunities to bring hope to those veterans still living with the trauma of their military experiences.”

Mydecine Chief Medical Officer, Dr. Rakesh Jetly, said, “The team is thrilled to be conducting studies within the veteran population where the help is needed most. During my 31 years as a medical officer and psychiatrist in the Canadian Armed Forces, I have seen first hand the impact PTSD has on our vets and their families. Sadly, many soldiers and veterans do not respond to the evidence-based treatments readily available to them and the search is on for new safe and effective treatments. Our troops fight and sacrifice together, so it only makes sense that we help them heal together.”

Mydecine CEO, Josh Bartch, said, “This partnership serves as another significant opportunity to expand our clinical trials and deliver on our mission to develop safe and effective alternative medicine people can trust. There is a big unmet need when it comes to treating PTSD and other mental health conditions, especially within the veteran population, and this partnership demonstrates the strong progress we continue to make in bringing psychoactive-assisted psychotherapies to the forefront of the market and bring hope for all those struggling with these conditions.”

Stay up to date and sign-up for Mydecine’s newsletter by scrolling to the bottom of this page.

About Mydecine Innovations Group

Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology and digital technology company developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. Mydecine Innovations Group was founded in 2020 on the guiding principle that there is a significant unmet need and lack of Innovations in the mental health and treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction, and other mental health disorders. Mydecine Innovations Group’s business model combines clinical trials and data outcome, technology, scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way we treat mental health disorders. Mydecine Innovations Group’s vision is to bridge the current gap between what the cognitive healthcare system currently provides with the needs of the patients. Mydecine Innovations Group is headquartered in Denver, Colorado, USA, with international offices in Leiden, Netherlands.

Learn more at: www.mydecine.com and follow the company on Twitter, Instagram, and LinkedIn.

For more information, please contact:

Investor & Media Contact
Morgan Kervitsky, Director of Marketing
(720) 689-4638
contact@mydecineinc.com

On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.

Primary Logo

Source: Mydecine Innovations Group Inc.

Released January 24, 2022

Posted on

New York could be the next state to legalize psilocybin therapy

New York Lawmaker Files Bill To Legalize Medical Psilocybin Treatments, With Focus On First Responders And Veterans

New York assemblyman Pat Burke (D) filed a bill that would legalize psilocybin therapy and create a $2M grant program to ensure veterans and first responders can access the treatment.

If passed, therapists would be able to certify patients for psilocybin therapy after completing a two-hour training course through the Department of Health.

PDF of article

Posted on

Reboot your brain 

‘Magic’ Mushrooms, Ecstasy, Other Psychedelics Could Become Legal in California

Marcus Capone, a former Navy SEAL who was battling PTSD, finally got his life back after travelling to Mexico for an ibogaine treatment. 

He instantly felt like a huge weight had been lifted, as if his brain “was rebooted like a new operating system.”

“You can’t hide from the medicine. It’s going to reach down and it’s going to pull out everything that is affecting you,” he explains.

PDF of article

Ibogaine is a psychedelic substance found in the root  bark of the iboga tree! Learn more here.

Posted on

Ketamine One Subsidiary IRP Health Opens Two New Veteran-Focused Clinics

Ketamine One Subsidiary IRP Health Opens Two New Veteran-Focused Clinics

The Previously Announced Open Label Study of Patients with PTSD Who Are Undergoing IRP Health’s Proprietary 12-Week Physical Therapy Program Has Received Ethics Approval

VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: 6FC), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly owned subsidiary, IRP Health Ltd. (“IRP” or the “Subsidiary”), recently opened its Comox Valley and Ottawa clinics (the “Two Clinics”). As previously announced, the Two Clinics are veteran-focused facilities and multidisciplinary in nature. To date, IRP has successfully performed over 10,000 unique treatments for past or present personnel of the Canadian Armed Forces and the Royal Canadian Mounted Police (“RCMP”), as well as first responders including firefighters, law enforcement officers, paramedics and emergency medical technicians.

The Comox Valley location is located at 780 30th Street in Courtenay, British Columbia, as the Comox Valley is one of the top retirement destinations in Canada for military veterans. The clinic is currently past the mid-way point of its inaugural program for RCMP personnel. The Ottawa clinic is located at #305 1385 Bank Street, in an area that has a local population of over 9,000 veterans. The clinic’s practitioners have begun providing veterans with private, mental health-focused Occupational Therapy sessions. IRP continues to work toward establishing clinic locations in Halifax and Surrey, as also previously announced.

Additionally, the previously announced open label study of patients with post-traumatic stress disorder (the “PTSD Study”) who are undergoing IRP’s proprietary, 12-week physical therapy program, in affiliation with Ketamine One’s wholly owned contract research organization KGK Science Inc (“KGK”), has recently received ethics approval. The next stage in preparation for the PTSD Study is to initiate a participant recruitment campaign and KGK expects to begin data collection early in 2022. A secondary benefit of the PTSD Study is that it will provide an opportunity for veterans who do not qualify for funding through Veterans Affairs Canada to participate in IRP’s beneficial program.

Management Commentary

“I would like to commend Steven Inglefield and his team for getting IRP’s Comox Valley and Ottawa clinics to operational status and for beginning to treat veterans and first responders in multidisciplinary ways. Ketamine One continues to be a leader in mental health in Canada, and North America, thanks to the hard work of its employees,” said Adam Deffett, Interim CEO of Ketamine One. “I am also excited about the advancement of the PTSD Study, which is a great example of two of our subsidiaries, IRP and KGK, working together with the goal of advancing the field mental health. As Canada’s only group of physical rehabilitation clinics exclusively treating members of the veteran and first responder population, IRP is filling a critical role in providing customized treatment programs for patients and is seeing strong demand for its services,” added Mr. Deffett.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly-owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

“Adam Deffett”
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Posted on

Healing veterans with DMT

DMT and PTSD

In honour of Veteran’s Day, we’re sharing the story of how a Special Ops veteran changed his life with DMT.

Asher Gibson was diagnosed with PTSD and traumatic brain injury after countless combats across the world. Prescription medications began to dominate his life, so he turned to psychedelic healing.

After smoking DMT, the powerful compound found in ayahuasca, Asher was blasted out of his body and traveled through different dimensions to the beginning of time.

“I remember my whole head being ecstatic and numb, like the most wonderful electrical massage on my brain. The feeling moved down my neck and shoulders and eventually filled my entire body.”

After the trip, Asher’s debilitating neck and shoulder pain was almost non-existent and his mental state subsided to manageable levels. He is no longer dependent on prescription drugs.

“While DMT isn’t the magic button that fixes everything, I believe it’s a powerful guide to help you do the work yourself,” he explains.

To bring this kind of relief to other veterans, consider supporting the Heroic Hearts Project – a non-profit organization that provides ayahuasca retreats for veterans with combat experience or military sexual trauma.

PDF of article